TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16209901

Group type: EXPERIMENTAL
Intervention: Unstable shoe (Masai Barefoot Technology, MBT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 8
Study: 12885095

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 5 mg/day, increased by 5 mg/week to a maximum of 30 mg/day for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 27
Study: 11533770

Group type: EXPERIMENTAL
Intervention: 100 mg rectal diclofenac immediately after cesarean section followed by 50 mg at 12 hours and 100 mg at 36 hours after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no diclofenac suppositories)
Number of subjects: 40
Study: 9105222

Group type: EXPERIMENTAL
Intervention: Continuous propofol sedation (CP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 121
Study: 8415931

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Habitual caffeine usage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender (females)
Number of subjects: 0
Study: 3698850

Group type: EXPERIMENTAL
Intervention: Polychemotherapy with carmustine, hydroxycarbamide and dacarbazine before and up to five times after surgery
Number of subjects: 33

Group type: COMPARATOR
Intervention: Surgical treatment alone
Number of subjects: 33
Study: 30815998

Group type: EXPERIMENTAL
Intervention: Deep anesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Light anesthesia
Number of subjects: 120
Study: 29618322

Group type: EXPERIMENTAL
Intervention: Sequential probability ratio test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized incidence ratio
Number of subjects: 0
Study: 27184139

Group type: EXPERIMENTAL
Intervention: Antagonist rescue combined with cabergoline
Number of subjects: 236

Group type: COMPARATOR
Intervention: Cabergoline alone
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Both groups (Antagonist rescue combined with cabergoline and Cabergoline alone)
Number of subjects: 236
Study: 25412095

Group type: EXPERIMENTAL
Intervention: Fully covered, self-expanding metal stents (FCSEMSs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 50
Study: 22623316

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: MBSR and AE (compared to untreated group)
Number of subjects: 56
Study: 20600255

Group type: EXPERIMENTAL
Intervention: Decided to do (DTD) screening tests
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Not considering or undecided (NCU) about screening
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Had never heard of (NHO) screening tests
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Prior cancer screening
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Belief in screening importance
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Gender (female)
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Race (white)
Number of subjects: 1515
Study: 17511854

Group type: EXPERIMENTAL
Intervention: Interferon beta 1a 30 mug intramuscularly once a week for 3 years
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo intramuscularly once a week for 3 years
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Interferon beta 1a
Number of subjects: 217
Study: 14725822

Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11068835

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 50
Study: 9376994

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Activated CD8 T cells (HLA-DR positivity)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: %CD8 T cells and serum IL-6 levels
Number of subjects: 57
Study: 8404785

Group type: EXPERIMENTAL
Intervention: Ethyl Ester (EE) fish oil concentrate (2.2 g EPA, 1.2 g DHA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Triglyceride (TG) fish oil concentrate (2.2 g EPA, 1.4 g DHA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ethyl Ester (EE) fish oil concentrate
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ethyl Ester (EE) and Triglyceride (TG) fish oils
Number of subjects: 31
Study: 3701583

Group type: EXPERIMENTAL
Intervention: Counselors who were more successful at biasing their clients' expectancies
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Clients who were more susceptible to counselor bias
Number of subjects: 78
Study: 30966728

Group type: EXPERIMENTAL
Intervention: 4 mg single-dose submucosal betamethasone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 43
Study: 28256747

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir (EBR/GZR) 50 mg/100 mg for 12 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir (EBR/GZR)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo (Deferred-Treatment Group)
Number of subjects: 159
Study: 25877363

Group type: EXPERIMENTAL
Intervention: High condylectomy with postsurgical orthodontic therapy (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High condylectomy without postsurgical orthodontic therapy (group B)
Number of subjects: 40
Study: 24165906

Group type: EXPERIMENTAL
Intervention: Tiotropium solution 5 µg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Powder 18 µg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 22629311

Group type: EXPERIMENTAL
Intervention: Overfeeding (OF) diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Weight maintaining (WM) diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sedentary time during OF
Number of subjects: 21
Study: 19565742

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-acupuncture (placebo acupuncture)
Number of subjects: 0
Study: 17674637

Group type: EXPERIMENTAL
Intervention: Stage-matched intervention group (n = 165)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Standard intervention group (n = 176)
Number of subjects: 507

Group type: COMPARATOR
Intervention: No-contact control group (n = 166)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Stage-matched intervention group (women)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Standard intervention group (women)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control group (women)
Number of subjects: 507
Study: 15464496

Group type: EXPERIMENTAL
Intervention: Leukocyte filtration during cardiopulmonary bypass (CPB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leukocyte filtration during CPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no leukocyte filtration)
Number of subjects: 40
Study: 10722499

Group type: EXPERIMENTAL
Intervention: Oral artesunate (2 mg/kg of body weight)
Number of subjects: 19
Study: 9197354

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg p.o. t.i.d.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1491608

Group type: EXPERIMENTAL
Intervention: Marine oil‐supplemented formula
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 65
Study: 3988972

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34
Study: 30240980

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 94
Study: 28639467

Group type: EXPERIMENTAL
Intervention: Gemcitabine diluted from a concentrate for solution for infusion (CSI) containing ethanol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lyophilized powder without ethanol (control)
Number of subjects: 24
Study: 27233237

Group type: EXPERIMENTAL
Intervention: Health literacy intervention (an 18‐week program with health knowledge and skills embedded in language, literacy, and numeracy training)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard Language Literacy and Numeracy (LLN) program (usual LLN classes, specifically excluding health content)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Health literacy intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard Language Literacy and Numeracy (LLN) program
Number of subjects: 300
Study: 25427568

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program including rehabilitative therapy, intake of hyperproteic nutritional shakes, memory workshop, and medication review.
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control group receiving recommendations on nutrition, healthy lifestyles, and home risks.
Number of subjects: 352
Study: 23609385

Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy (10 to 80 mg daily for up to 14 weeks)
Number of subjects: 166
Study: 20465435

Group type: EXPERIMENTAL
Intervention: Maltitol chocolate (5 to 15 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucrose chocolate (placebo)
Number of subjects: 0
Study: 18469202

Group type: EXPERIMENTAL
Intervention: Visceral Adipose Tissue (VAT)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Visceral Adipose Tissue (VAT) after addition of HOMA-IR
Number of subjects: 382

Group type: COMPARATOR
Intervention: Body Mass Index (BMI) and Subcutaneous Adipose Tissue (SAT)
Number of subjects: 382
Study: 16614984

Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of 50 g of glucose in 300 mL saline (16.7%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of 50 g of glucose in 600 mL saline (8.3%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of 50 g of glucose in 1200 mL saline (4.1%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (0.9%) infusion after glucose infusion
Number of subjects: 8
Study: 12595910

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 10946333

Group type: EXPERIMENTAL
Intervention: Bonded allograft and homograft restorations
Number of subjects: 20
Study: 8635376

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol, 50 microg twice a day for seven doses
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1442650

Group type: EXPERIMENTAL
Intervention: Experimental reduced-protein formula (13 g/L protein, whey-casein ratio 40:60, added tryptophan 490 mumol/L)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional formula (15 g protein/L, whey-casein ratio 60:40)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 95
Study: 31691413

Group type: EXPERIMENTAL
Intervention: High-intensity internet intervention (n=72)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Low-intensity internet intervention (n=71)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Waiting-list control (n=23)
Number of subjects: 166
Study: 30562195

Group type: EXPERIMENTAL
Intervention: Fast-track radioiodine ablative therapy (RIT) 1 week after thyroidectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (RIT planned 4 to 6 weeks after surgery)
Number of subjects: 20
Study: 27837950

Group type: EXPERIMENTAL
Intervention: Biventricular congenital heart disease (CHD) infants
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy control infants
Number of subjects: 48
Study: 26537053

Group type: EXPERIMENTAL
Intervention: Raloxifene (120 mg oral once daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (identical to raloxifene)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 23524843

Group type: EXPERIMENTAL
Intervention: Intensive sensory and motor stimulation program (16 sessions in rehabilitation center, daily sessions at home for 8 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intensive sensory and motor stimulation program
Number of subjects: 21
Study: 22114905

Group type: EXPERIMENTAL
Intervention: FlexTouch (FT)
Number of subjects: 300
Study: 20028261

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%/Timolol 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dorzolamide/Timolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Brimonidine plus Dorzolamide/Timolol
Number of subjects: 60
Study: 17661193

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study: 16234518

Group type: EXPERIMENTAL
Intervention: Anastrozole (Arimidex)
Number of subjects: 9366

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 9366
Study: 11865387

Group type: EXPERIMENTAL
Intervention: Axial traction of the cervical spine after extubation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no axial traction)
Number of subjects: 30
Study: 10077966

Group type: EXPERIMENTAL
Intervention: Ethisorp patches
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lyodura
Number of subjects: 12

Group type: COMPARATOR
Intervention: Syspurderm
Number of subjects: 12

Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 12
Study: 7594125

Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 840

Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 840

Group type: COMPARATOR
Intervention: Very-low-protein diet
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Self-monitoring and dietitian support
Number of subjects: 840
Study: 2149510

Group type: EXPERIMENTAL
Intervention: Zoladex plus tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoladex alone
Number of subjects: 0
Study: 86845

Group type: EXPERIMENTAL
Intervention: Hospital A (operated upon 66 out of 206 patients, 32%)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Hospital B (operated upon 44 out of 96 patients, 46%)
Number of subjects: 302
Study: 31983598

Group type: EXPERIMENTAL
Intervention: Verum group (TENS therapy)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 151
Study: 31845167

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 164
Study: 31216880

Group type: EXPERIMENTAL
Intervention: Face-to-face training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard information program (control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Face-to-face training (per-protocol analysis)
Number of subjects: 63
Study: 27076283

Group type: EXPERIMENTAL
Intervention: 30% one repetition maximum (1RM) with blood flow restriction (BFR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20% one repetition maximum (1RM) with blood flow restriction (BFR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 70% one repetition maximum (1RM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20% and 30% to failure
Number of subjects: 40
Study: 23941781

Group type: EXPERIMENTAL
Intervention: self‐focused attention and safety behaviours experiment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: individual cognitive therapy (CT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: interpersonal therapy (IPT)
Number of subjects: 32
Study: 22547421

Group type: EXPERIMENTAL
Intervention: Early ART (initiate ART immediately)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Deferred ART (defer treatment until CD4 count <350 cells/µL)
Number of subjects: 4000
Study: 21276222

Group type: EXPERIMENTAL
Intervention: Standard Light Treatment (SLT) at 10,000 lux for 30 minutes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-intensity Blue-enriched Light Treatment (BLT) at 750 lux for 30 minutes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both SLT and BLT
Number of subjects: 22
Study: 19290010

Group type: EXPERIMENTAL
Intervention: School-based intervention promoting low-fat dairy products and whole-grain bread, eliminating sweets and sweetened drinks, increasing physical activity by 30 min/day during school time
Number of subjects: 3135

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 3135

Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 3135

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3135
Study: 17132082

Group type: EXPERIMENTAL
Intervention: Hue scaling technique under five different illuminations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked control experiment with test surfaces from one illumination condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized order control experiment
Number of subjects: 0
Study: 14720270

Group type: EXPERIMENTAL
Intervention: Butterbur (BB) 25 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study: 11247897

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS)
Number of subjects: 6394

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) combined with faecal occult blood testing
Number of subjects: 6394
Study: 9118762

Group type: EXPERIMENTAL
Intervention: GenHevac B
Number of subjects: 71

Group type: COMPARATOR
Intervention: Engerix B
Number of subjects: 71
Study: 8505831

Group type: EXPERIMENTAL
Intervention: Group B: 2000 mL of 5% glucose in water or saline plus 1000 mL of 5% amino acid solution per day (approximately 10 kcal/kg per day and 1 g of protein per kilogram per day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group C: 2000 mL of 5% glucose in water or saline plus 500 mL of 5% amino acid solution and 500 mL of 10% fat emulsion (approximately 20 kcal/kg per day and 0.5 g of protein per kilogram per day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group A: 3000 mL of a 5% glucose in water or glucose in saline infusion per day (approximately 10 kcal/kg per day)
Number of subjects: 42
Study: 3318754

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual supportive therapy
Number of subjects: 80
Study: 29883964

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 40
Study: 27406781

Group type: EXPERIMENTAL
Intervention: Commitment group (n=14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Information group (n=13)
Number of subjects: 27
Study: 25138332

Group type: EXPERIMENTAL
Intervention: True oximetry measurements
Number of subjects: 213

Group type: COMPARATOR
Intervention: Altered oximetry measurements (3 percentage points above true values)
Number of subjects: 213
Study: 23092146

Group type: EXPERIMENTAL
Intervention: 20% carbamide peroxide bleaching gel (Opalescence PF 20)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control specimens stored in water (one‐day and two‐month)
Number of subjects: 0
Study: 19904246

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20-40 mg daily
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Both treatments (Esomeprazole and LARS)
Number of subjects: 514
Study: 18048059

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 10 ml
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 30 ml
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 41
Study: 15624072

Group type: EXPERIMENTAL
Intervention: PRN patients receiving RCT study medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRN patients with schizophrenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRN patients with bipolar I disorder
Number of subjects: 0
Study: 12584783

Group type: EXPERIMENTAL
Intervention: Yizhi mixture (YZM)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ritalin
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Combined treatment of YZM and Ritalin
Number of subjects: 210
Study: 10600792

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: hCG
Number of subjects: 0
Study: 7717739

Group type: EXPERIMENTAL
Intervention: Viable L casei strain GG
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inactivated L casei strain GG
Number of subjects: 25
Study: 1843963

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) solution administered at a rate of 0.5 liters daily for 8 days (Group 1: placebo first week, PEG second week)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) solution administered at a rate of 0.5 liters daily for 8 days (Group 2: PEG first week, placebo second week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) solution
Number of subjects: 34
Study: 6754062

Group type: EXPERIMENTAL
Intervention: Vincristine 1 mg/m2, doxorubicin 40 mg/m2 on day one and cyclophosphamide 200 mg/m2 orally days 3‐6 (VAC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cyclophosphamide 350 mg/m2, methotrexate 20 mg/m2, and 5‐fluorouracil 350 mg/m2 (CMF) intravenously
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: VAC
Number of subjects: 81

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 81

Group type: COMPARATOR
Intervention: VAC and CMF
Number of subjects: 81
Study: 29392787

Group type: EXPERIMENTAL
Intervention: Sarolaner
Number of subjects: 241

Group type: COMPARATOR
Intervention: Moxidectin/imidacloprid
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 241
Study: 26447868

Group type: EXPERIMENTAL
Intervention: Breath-holding (BH) high-pitch helical CTPA
Number of subjects: 99

Group type: COMPARATOR
Intervention: Free-breathing (FB) high-pitch helical CTPA
Number of subjects: 99
Study: 24503205

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30